This mutation is equivalent to the pathological de novo dominant missense mutation R80H, thus expanding the potential therapeutic usage of these molecules also to other non-adPEO pathologies caused by dominant ANT1 mutations. The gene discussed is SLC25A4; the disease is autosomal dominant progressive external ophthalmoplegia.